Biomarker Analysis and Biomonitoring
We offer a large portfolio of ISO 17025 accredited methods in biomarker analysis and biomonitoring with more than 40 years of experience! We developed 70+ robust, highly sensitive assays to support your (pre)clinical and epidemiological studies in compliance with GLP, GCP. Our biomarker data were used to support numerous submissions to regulatory agencies.
Frequently searched biomarkers
We offer a large portfolio of bioanalytical methods for exposure assessment, biomarker identification, metabolite profiling and DMPK
Biomonitoring
We provide a range of validated LC-MS and GC-MS methods for accurate determination of environmental chemicals in biological samples such as urine and plasma. Our methods have been used in various HBM campaigns for exposure assessment of environmental chemicals such as VOCs, PAHs, nicotine, phthalates, pesticides and fragrances. Our non-targeted high resolution MS platform is utilized in exposomics - the comprehensive exploration of exposure, their sources and exposure-related health implications. Our aim is to enhance understanding of the interaction of our exposure to chemicals with the human body, promoting health and sustainability.
Tobacco Harm Reduction
With 40 years of experience, ABF is a global leader in bioanalysis of exposure biomarkers related to tobacco and new nicotine products. We've analyzed samples for numerous studies, using the largest set of validated methods in tobacco harm reduction. Our clients benefit from our ISO 17025-accredited and GCP/GLP-compliant procedures for biomarker and nicotine PK analysis in regulatory submissions to FDA for Premarket Tobacco Applications (PMTA) and Modified Risk Tobacco Product Applications (MRTPA). We continuously develop new methods and strive to stay scientifically updated, for instance applying our non-targeted high-resolution MS methods to identify product-use specific exposure. Our goal is to responsibly assist clients in introducing new nicotine products.
Bioanalysis of Cannabinoids
ABF leads scientific development with innovative methods for precise cannabis and cannabinoids analysis. Our GLP and GCP compliant assays comprise THC, CBD, CBG, and THCV as well as their metabolites in plasma for pharmacokinetic and toxicokinetic studies, exposure assessment, and risk evaluation. We aim to support responsible introduction of new products. Choose ABF for accurate and sensitive cannabinoid bioanalysis.
Bioanalytical Solutions for Pharma
As an ISO 17025 accredited and GLP certified lab, we provide the pharmaceutical industry with a full range of bioanalytical services, supporting all stages of drug development. Our expertise spans PK/TK/PD studies, metabolite profiling, non-targeted screening, biomarker analysis, and impurity identification using advanced LC-MS technologies. With decades of experience, we ensure quality, accuracy, and swift project turnaround. Our automated data processes make us your top choice for bioanalytical services.
Our service goes beyond sample analysis
We help customers to evaluate and interpret data
ABF is an ISO 17025 accredited and GLP-certified bioanalytical contract research laboratory with more than four decades of experience in method development, validation and application in the field of biomarkers, biomonitoring and DMPK studies
About us
Accreditation & Quality Management
ABF holds an accreditation according to ISO17025:2018. All analytical methods are fully validated according to FDA ICH M10 Guidance for Industry -Guidelines on Bioanalytical Method Validation and Study Sample Analysis. ABF's laboratory procedures were established to comply with the principles of** GLP** and GCP. Our quality system and laboratory work is monitored by internal and external audits on a regular basis. External audits are performed by governmental authorities like the LGL (Bavarian State Office for Health and Food Safety) and accreditation bodies like the German DAkkS (German Accreditation Body) as well as Sponsor-initiated project audits.
What's your need?
We are constantly establishing new bioanalytical methods according to our customers' needs. For any specific request please contact us directly.
Recent Publications & Conference Contributions
Analysis of mercapturic acids in biobanked urine samples – Tackling the data gap in human biomonitoring of VOCs in Europe
Nikola Pluym, Therese Burkhardt, Till Weber, Max Scherer, Marike Kolossa-Gehring
ISES Europe Workshop 2026, Dublin, Ireland
Beyond cotinine: Implementing a comprehensive biomarker panel for nicotine product use monitoring in Europe
Nikola Pluym, Therese Burkhardt, Max Scherer
ISES Europe Workshop 2026, Dublin, Ireland
The MAGNIFICAT Study: Assessing the Impact of Cigarette Substitution with E-Cigarettes on the Exposure Profile in Dual Users-Results after 30 days of dual use
Max Scherer, Riccardo Polosa, Simona Veigl, Nikola Pluym, Therese Burkhardt, Jonathan Belsey, Christopher Russell, Pascale Caponnetto, Jakub Weglarz, Davide Campagna
CORESTA PSPT 2025, Annecy, France
Wastewater-based epidemiology: Monitoring use prevalence of combustible cigarettes and new generation tobacco and nicotine products on a population level
Nikola Pluym, Gerhard Scherer, Max Scherer
CORESTA PSPT 2025, Annecy, France
Analysis of caffeine in human plasma by LC-MS/MS
Max Scherer, Johanna Lehocky, Nikola Pluym
CORESTA PSPT 2025, Annecy, France
Investigations on human biomonitoring for assessing the exposure to synthetic rose oxide in the general population
Carmen Tiwald, Veronika Spindler, Max Scherer, Nikola Pluym, Oliver Peschel, Edgar Leibold, Gerhard Scherer
ISBM 13, Milan, Italy
Revealing the urinary exposome of smokers, vapers, HTP users and pouch consumers by high-resolution LC-MS –an important step in the identification of use-specific biomarkers of exposure
Veronika Spindler, Alpeshkumar Kachhadia, Nikola Pluym, Therese Burkhardt, Gerhard Scherer, Max Scherer
ISBM 13, Milan, Italy
Investigations on human biomonitoring for assessing the exposure to synthetic rose oxide in the general population
Carmen Tiwald, Veronika Spindler, Max Scherer, Nikola Pluym, Oliver Peschel, Edgar Leibold, Gerhard Scherer
Journal of Chromatography B
Wastewater-Based Epidemiology (WBE): Potential Application for Assessing the Use of Conventional and New Generation Tobacco and Nicotine Products
Gerhard Scherer, Nikola Pluym, Max Scherer
Contributions to Tobacco & Nicotine Research
Assessing the exposure to the UV filter DHHB in urine samples from the German Environmental Specimen Bank (2000–2021): Evaluating the impact of a potential impurity of di-n-hexyl phthalate in DHHB
Max Scherer, Gerhard Scherer, Kirsten Riedel, Holger M. Koch, Sonja A. Wrobel, Aline Murawski, Nora Lemke, Till Weber, Nikola Pluym, Marike Kolossa-Gehring
International Journal of Hygiene and Environmental Health